PMID- 36819558
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230224
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 11
IP  - 2
DP  - 2023 Jan 31
TI  - A novel human multiple myeloma cell line with a 1q21 gain genetic abnormality and 
      CKS1B overexpression.
PG  - 126
LID - 10.21037/atm-22-5741 [doi]
LID - 126
AB  - BACKGROUND: Multiple myeloma (MM) is an incurable hematologic malignancy mainly 
      due to its cytogenetic abnormalities. Therefore, it is important to establish 
      permanent malignant MM cell lines as tools to develop more effective therapies. 
      METHODS: Pleural effusion cells of a 70-year-old patient was collected to 
      establish the CZ2 cell line. Characterization of CZ2 was determined with 
      nephelometry, flow cytometry, fluorescence in situ hybridization (FISH), and 
      chromosomal microarray analysis (CMA). Western blotting analysis was adopted to 
      determine protein expression. Cell viability was measured by the 3-(4,5-dimethyl 
      thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. RESULTS: We 
      established and characterized a new MM cell line, CZ2. Using nephelometry and 
      flow cytometry, cells with typical plasma cell morphology but not classical 
      plasma cell phenotype were found to be non-immunoglobulin-secretary cells. FISH 
      analysis of cells revealed a unique characteristic, namely, that there was only 
      gain of the 1q21 region (1q21+). No other common cytogenetic abnormalities in MM, 
      such as deletion of 17p (17p-), deletion of 13q (13q-), or translocation of 
      immunoglobulin heavy chain (IgH), were observed. In addition, the original cell 
      line maintains its single cytogenetic abnormality. Meanwhile, we observed through 
      western blotting that CDC28 protein kinase regulatory subunit 1B (CKS1B), an 
      adverse prognostic gene located in the 1q21 region, was highly expressed in CZ2. 
      Knockdown of CKS1B reduced cell viability and also increased the levels of 
      cleaved-poly(ADP-ribose) polymerase (cleaved-PARP) and cleaved-caspase3. 
      CONCLUSIONS: CZ2 provides a suitable material for cellular and molecular studies 
      of MM with only a 1q21 abnormality. This cell line is characterized by a gain of 
      1q21, and the high expression of CKS1B is an important model for studies of 
      myeloma cell growth and drug resistance during therapy.
CI  - 2023 Annals of Translational Medicine. All rights reserved.
FAU - He, Jie
AU  - He J
AD  - Nuclear Radiation Injury Protection and Treatment Department, Navy Medical Center 
      of PLA, Shanghai, China.
FAU - Yi, Ke
AU  - Yi K
AD  - Nuclear Radiation Injury Protection and Treatment Department, Navy Medical Center 
      of PLA, Shanghai, China.
FAU - Zhang, Yajun
AU  - Zhang Y
AD  - Nuclear Radiation Injury Protection and Treatment Department, Navy Medical Center 
      of PLA, Shanghai, China.
FAU - Zhang, Hui
AU  - Zhang H
AD  - Myeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, Navy 
      Medical University, Shanghai, China.
FAU - Hou, Jian
AU  - Hou J
AD  - Myeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, Navy 
      Medical University, Shanghai, China.
AD  - Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Li, Rong
AU  - Li R
AD  - Nuclear Radiation Injury Protection and Treatment Department, Navy Medical Center 
      of PLA, Shanghai, China.
AD  - Myeloma and Lymphoma Center, Department of Hematology, Changzheng Hospital, Navy 
      Medical University, Shanghai, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC9929770
OTO - NOTNLM
OT  - 1q21 gain/amplification
OT  - CDC28 protein kinase regulatory subunit 1B (CKS1B)
OT  - Multiple myeloma (MM)
OT  - cell line
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://atm.amegroups.com/article/view/10.21037/atm-22-5741/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2023/02/24 06:00
MHDA- 2023/02/24 06:01
PMCR- 2023/01/31
CRDT- 2023/02/23 10:04
PHST- 2022/10/20 00:00 [received]
PHST- 2023/01/14 00:00 [accepted]
PHST- 2023/02/23 10:04 [entrez]
PHST- 2023/02/24 06:00 [pubmed]
PHST- 2023/02/24 06:01 [medline]
PHST- 2023/01/31 00:00 [pmc-release]
AID - atm-11-02-126 [pii]
AID - 10.21037/atm-22-5741 [doi]
PST - ppublish
SO  - Ann Transl Med. 2023 Jan 31;11(2):126. doi: 10.21037/atm-22-5741.